Landscape Capital Management L.L.C. Purchases 59,742 Shares of DexCom, Inc. (NASDAQ:DXCM)

Landscape Capital Management L.L.C. increased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 1,834.8% in the third quarter, Holdings Channel.com reports. The institutional investor owned 62,998 shares of the medical device company’s stock after buying an additional 59,742 shares during the period. Landscape Capital Management L.L.C.’s holdings in DexCom were worth $4,223,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the company. Capital Insight Partners LLC increased its holdings in DexCom by 2.5% in the second quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock worth $418,000 after purchasing an additional 90 shares in the last quarter. HM Payson & Co. boosted its stake in DexCom by 6.0% during the first quarter. HM Payson & Co. now owns 1,780 shares of the medical device company’s stock worth $247,000 after acquiring an additional 100 shares in the last quarter. Clear Creek Financial Management LLC boosted its stake in DexCom by 4.2% during the second quarter. Clear Creek Financial Management LLC now owns 2,961 shares of the medical device company’s stock worth $336,000 after acquiring an additional 120 shares in the last quarter. SeaCrest Wealth Management LLC grew its holdings in DexCom by 3.6% in the second quarter. SeaCrest Wealth Management LLC now owns 4,421 shares of the medical device company’s stock worth $501,000 after purchasing an additional 152 shares during the period. Finally, Securian Asset Management Inc. raised its holdings in shares of DexCom by 0.7% during the second quarter. Securian Asset Management Inc. now owns 22,866 shares of the medical device company’s stock valued at $2,593,000 after purchasing an additional 161 shares during the period. Institutional investors own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

DXCM has been the subject of a number of research analyst reports. Royal Bank of Canada decreased their target price on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Morgan Stanley decreased their target price on shares of DexCom from $120.00 to $75.00 and set an “equal weight” rating for the company in a research report on Friday, July 26th. JPMorgan Chase & Co. raised their price target on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Robert W. Baird lifted their price target on DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, August 5th. Finally, Oppenheimer lowered their price objective on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $104.59.

Insider Transactions at DexCom

In related news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This trade represents a 0.28 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at $5,217,436.65. This represents a 0.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.30% of the stock is currently owned by insiders.

DexCom Stock Performance

Shares of DXCM opened at $75.24 on Thursday. The stock has a 50-day moving average price of $70.29 and a 200-day moving average price of $90.44. The company has a market cap of $29.39 billion, a PE ratio of 45.05, a price-to-earnings-growth ratio of 2.30 and a beta of 1.17. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.